The Latest in Non-Hodgkin Lymphoma Hub

Novartis CAR T-cell therapy adds a lymphoma indication

May 3, 2018

Aggressive Lymphomas

Five-year survival for non-Hodgkin lymphoma tops 71%

May 2, 2018

Aggressive Lymphomas

FDA places partial hold on trials after secondary lymphoma

April 25, 2018

Aggressive Lymphomas

Venetoclax shows muscle against CLL relapsed after idelalisib

April 18, 2018

Indolent Lymphoma

PDPK1 could be novel target in MCL

April 13, 2018

Aggressive Lymphomas

New genetic subtypes could facilitate precision medicine in DLBCL

April 11, 2018

Aggressive Lymphomas

FDA grants priority review of follicular lymphoma drug

April 11, 2018

Indolent Lymphoma

Updated CLL guidelines incorporate a decade of advances

April 6, 2018

Indolent Lymphoma

Lenalidomide yields responses in a rare cutaneous lymphoma

April 3, 2018

Aggressive Lymphomas

Ibrutinib plus venetoclax is active in mantle cell lymphoma

March 28, 2018

Aggressive Lymphomas

VIDEO: How to prepare PTCL patients for transplant

March 27, 2018

Aggressive Lymphomas

Experimental voxtalisib shows mixed results in phase 2 study

March 22, 2018

Aggressive Lymphomas

FDA updates breast implant–associated lymphoma cases, risk

March 22, 2018

Indolent Lymphoma

Time to rethink MCL treatment, trial design

March 14, 2018

Aggressive Lymphomas

CAR T before transplant yields durable remission in B-cell malignancies

March 14, 2018

Aggressive Lymphomas